|
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
METABOLISM, TRANSPORT, AND PHARMACOGENOMICS
Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (S.R.F., C.M.S., H.W.); Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental and Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina (T.S., M.N.); and CellzDirect, Inc., Pittsboro, North Carolina (E.L.L.)
Accumulated evidence suggests that cross-talk between the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) results in shared transcriptional activation of CYP2B and CYP3A genes. Although most data imply symmetrical cross-regulation of these genes by rodent PXR and CAR, the actual selectivities of the corresponding human receptors are unknown. The objective of this study was to evaluate the symmetry of human (h) PXR and hCAR cross-talk by comparing the selectivities of these receptors for CYP2B6 and CYP3A4. Human hepatocyte studies revealed nonselective induction of both CYP2B6 and CYP3A4 by hPXR activation but marked preferential induction of CYP2B6 by selective hCAR activation. Gel shift assays demonstrated that hPXR exhibited strong and relatively equal binding to all functional response elements in both CYP2B6 and CYP3A4 genes, whereas hCAR displayed significantly weak binding to the CYP3A4 proximal ER6 motif. In cell-based transfection assays, hCAR displayed greater activation of CYP2B6 reporter gene expression compared with CYP3A4 with constructs containing both proximal and distal regulatory elements. Furthermore, in agreement with binding observations, transfection assays using promoter constructs containing repeats of CYP2B6 DR4 and CYP3A4 ER6 motifs revealed an even greater difference in reporter activation by hCAR. In contrast, hPXR activation resulted in less discernible differences between CYP2B6 and CYP3A4 reporter gene expression. These results suggest asymmetrical cross-regulation of CYP2B6 and CYP3A4 by hCAR but not hPXR in that hCAR exhibits preferential induction of CYP2B6 relative to CYP3A4 because of its weak binding and functional activation of the CYP3A4 ER6.
Address correspondence to: Dr. Hongbing Wang, Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360. E-mail: wang4{at}email.unc.edu
This article has been cited by other articles:
![]() |
A. H. Tolson, H. Li, N. D. Eddington, and H. Wang Methadone Induces the Expression of Hepatic Drug-Metabolizing Enzymes through the Activation of Pregnane X Receptor and Constitutive Androstane Receptor Drug Metab. Dispos., September 1, 2009; 37(9): 1887 - 1894. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kozawa, M. Honma, and H. Suzuki Quantitative Prediction of in Vivo Profiles of CYP3A4 Induction in Humans from in Vitro Results with a Reporter Gene Assay Drug Metab. Dispos., June 1, 2009; 37(6): 1234 - 1241. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. McGinnity, G. Zhang, J. R. Kenny, G. A. Hamilton, S. Otmani, K. R. Stams, S. Haney, P. Brassil, D. M. Stresser, and R. J. Riley Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells Drug Metab. Dispos., June 1, 2009; 37(6): 1259 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. A. Fahmi, S. Boldt, M. Kish, R. S. Obach, and L. M. Tremaine PREDICTION OF DRUG-DRUG INTERACTIONS FROM IN VITRO INDUCTION DATA: Application of the Relative Induction Score Approach Using Cryopreserved Human Hepatocytes Drug Metab. Dispos., September 1, 2008; 36(9): 1971 - 1974. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Li, T. Chen, J. D. Stanton, T. Sueyoshi, M. Negishi, and H. Wang The Peripheral Benzodiazepine Receptor Ligand 1-(2-Chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide Is a Novel Antagonist of Human Constitutive Androstane Receptor Mol. Pharmacol., August 1, 2008; 74(2): 443 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hariparsad, B. A. Carr, R. Evers, and X. Chu Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction Drug Metab. Dispos., June 1, 2008; 36(6): 1046 - 1055. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Kharasch, D. Mitchell, R. Coles, and R. Blanco Rapid Clinical Induction of Hepatic Cytochrome P4502B6 Activity by Ritonavir Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1663 - 1669. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Richert, G. Tuschl, C. Viollon-Abadie, N. Blanchard, A. Bonet, B. Heyd, N. Halkic, E. Wimmer, H. Dolgos, and S. O. Mueller Species Differences in the Response of Liver Drug-Metabolizing Enzymes to (S)-4-O-Tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric Acid (EMD 392949) in Vivo and in Vitro Drug Metab. Dispos., April 1, 2008; 36(4): 702 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Healan-Greenberg, J. F. Waring, D. J. Kempf, E. A. G. Blomme, R. G. Tirona, and R. B. Kim A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor Drug Metab. Dispos., March 1, 2008; 36(3): 500 - 507. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Faucette, T.-C. Zhang, R. Moore, T. Sueyoshi, C. J. Omiecinski, E. L. LeCluyse, M. Negishi, and H. Wang Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 72 - 80. [Abstract] [Full Text] [PDF] |
||||